Biorce Brings Its Unconventional Car Ride Campaign to ESMO 2026

Biorce is bringing its clinical development experience to ESMO 2026, taking conversations about AI beyond the conference floor and onto the streets of Madrid.

Biorce ride campaign at ESMO 2026 Madrid

Madrid, Spain - [September 28, 2026] — Biorce, the global healthtech company born in Barcelona, Spain, today announced that it will bring its signature ride campaign to Madrid during ESMO 2026, giving attendees a new way to connect, explore, and discuss the future of AI in clinical development.

Following the success of its unconventional ride experience at ASCO 2026 in Chicago and BIO in San Diego, Biorce is once again ditching the traditional conference booth in favor of something a little more mobile. From October 24 through 26, two Mercedes-Benz V-Class vehicles will operate between 08:00 and 19:00, offering ESMO attendees rides from an authorized pickup point at IFEMA Madrid and nearby hotels, with drop-offs available anywhere guests need to go, including the airport.

“The best conversations don’t necessarily happen inside a conference booth,” said Pedro Coelho, Founder and CEO of Biorce. “After seeing the response to our ride experience at ASCO, we wanted to bring the concept to Madrid and create another space for people to experience what AI can mean for the future of clinical development.”

During the campaign, attendees will have the opportunity to experience Aika 2.0, Biorce’s AI-native operating system for clinical development, while travelling through Madrid. At the leading conferences in the US, the ride experience became a fitting metaphor for Aika 2.0 itself: clinical development is a journey, and the technology supporting it should help make that journey more connected, coordinated, and efficient. In Madrid, Biorce is taking that idea one step further, offering a first-hand look at the new product capabilities launching in October.

Reserve at: https://www.biorce.com/aika-ride-campaign

About Biorce

Biorce is an AI healthtech startup, building defensible AI solutions for clinical trial development. Its platform, Aika, is a continuous intelligent layer, from protocol decision to regulatory submission, enabling fewer amendments and a dramatic reduction of cost and time.